Pharmacoeconomic Analysis of Inhalation Drugs Availability Used in COPD Treatment

Relevance of the study and the presence of gaps in existing knowledge on topic. The use of inhalation bronchodilators and glucocorticosteroids (GCS) improves the functional parameters of the lungs in patients with chronic obstructive pulmonary disease (COPD), as well as reduces the number of middle and severe exacerbations. There are a large number of inhalation drugs in the modern Russian pharmaceutical market, which are both monocomponent and combinations of two and three drugs. Often, original and generic drugs have different costs and are not always economically or physically available to different population segments.

Thus, the aim of this study was to conduct a comparative pharmacoeconomic analysis of inhalation bronchodilators and anti-inflammatory drugs to determine the level of economic availability. 

Materials and Methods. Drugs from the group of adrenomimetics for inhalational use (ATC code R03A), anticholinolytic and GCS for inhalation used in the COPD treatment (ATC code R03B) were analyzed. Information about the price of drugs is obtained from the state register of maximum selling prices and the Internet resource "Apteka.ru". To evaluate the availability of the analyzed groups of drugs, solvency adequacy coefficients (Ca.s) and price liquidity indicators (Cliq) were calculated.

Results. The most available among the GCS was beclomethasone in form of a metered-dose inhalator (MDI) 50 mcg (Cliq = 52%; Ca.s = 0.338%), among short-acting emergency bronchodilators, salbutamol in MDI form 100 mcg (Cliq= 58%; Ca.s = 0.156%) was the most available. Greater availability was found for domestic drug manufacturers (95% CI: 0.690 - 1,000; p = 0.007), however, the opposite data were obtained for several drugs.

Conclusions. The obtained results show a heterogeneous structure among the levels of inhalation drugs availability used in COPD treatment. Taking into account the wide range of drug products, in order to inform medical and pharmaceutical workers in a timely way, it is advisable to systematically study these drug groups using pharmacoeconomic analysis methods.

1. Vogelmeier, C. F., Román-Rodríguez, M., Singh, D., Han, M. K., Rodríguez-Roisin, R., & Ferguson, G. T. (2020). Goals of COPD treatment: focus on symptoms and exacerbations. Respiratory medicine, 166, 105938. https://doi.org/10.1016/j.rmed.2020.105938

2. M. Heron, Deaths: Leading Causes for 2017, Natl. Vital Stat. Rep. 68(6) (2019) 1-77.

3. James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., ... & Briggs, A. M. (2018). Global, regional, and national incidence, preva-lence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet, 392(10159), 1789-1858. https://doi.org/10.1016/S0140-6736(18)32279-7

4. Концевая, А. В., Муканеева, Д. К., Баланова, Ю. А., Худяков, М. Б., & Драпкина, О. М. (2019). Экономический ущерб от болезней органов дыхания и хронической обструктивной болезни легких в Российской Федерации в 2016 году. Пульмонология, 29(2), 159-166. https://doi.org/10.18093/0869-0189-2019-29-2-159-166

5. Орлова, Е. А., Умерова, А. Р., Дорфман, И. П., Орлов, М. А., & Абдул-лаев, М. А. (2021). Оценка социально-экономического бремени хрони-ческой обструктивной болезни легких за 5-летний период–региональный аспект. Фармация и фармакология, 9(2), 130-138. https://doi.org/10.19163/2307-9266-2021-9-2-130-138

6. Mannino, D. M., & Buist, A. S. (2007). Global burden of COPD: risk fac-tors, prevalence, and future trends. The Lancet, 370(9589), 765-773. https://doi.org/10.1016/S0140-6736(07)61380-4

7. Орлова, Е. А., Дорфман, И. П., Орлов, М. А., Абдуллаев, М. А., & Ива-нова, С. В. (2020). Актуальные вопросы вакцинопрофилактики хрони-ческой обструктивной болезни легких в условиях современной клини-ческой практики. Астраханский медицинский журнал, 15(1). https://doi.org/10.17021/2020.15.1.84.98

8. Игнатова, Г. Л., Антонов, В. Н., & Родионова, О. В. (2015). Экономиче-ская оценка вакцинопрофилактики больных хронической обструктив-ной болезнью легких и ишемической болезнью серд-ца. Пульмонология, 25(3), 312-319. https://doi.org/10.18093/0869-0189-2015-25-3-312-319

9. Орлова, Е. А., Дорфман, И. П., Орлов, М. А., & Абдуллаев, М. А. (2021). Фармакоэкономическое обоснование проведения антипневмо-кокковой вакцинации в группах риска для профилактики внебольнич-ных пневмоний среди взрослого населения астраханской обла-сти. Фармация и фармакология, 8(6), 436-445. https://doi.org/10.19163/2307-9266-2020-8-6-436-445

10. Игнатова, Г. Л., Антонов, В. Н., & Блинова, Е. В. (2019). Анализ эффек-тивности совместной или последовательной вакцинации пневмококко-выми и гриппозными вакцинами у пациентов с хронической обструк-тивной болезнью легких. Терапевтический архив, 91(8). https://doi.org/10.26442/00403660.2019.08.000205

11. Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., ... & Agusti, A. (2017). Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 re-port. GOLD executive summary. American journal of respiratory and criti-cal care medicine, 195(5), 557-582. https://doi.org/10.1164/rccm.201701-0218PP

12. Singh, D., Agusti, A., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., ... & Vogelmeier, C. (2019). Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science com-mittee report 2019. European Respiratory Journal, 53(5). https://doi.org/10.1183/13993003.00164-2019

13. Naya, I., Tombs, L., Lipson, D. A., Boucot, I., & Compton, C. (2019). Im-pact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis. Respiratory research, 20(1), 1-11. https://doi.org/10.1186/s12931-019-1027-9

14. Орлова, Е. А., Дорфман, И. П., Орлов, М. А., Андреева, А. К., & Аб-дуллаев, М. А. (2021). Бронхолитическая и противовоспалительная те-рапия хронической обструктивной болезни легких с позиции взаимоза-меняемости. Пульмонология, 31(4), 518-529. https://doi.org/10.18093/0869-0189-2021-31-4-518-529

15. Волостная, В. М., Прокопенко, И. П., & Шестаков, Г. Н. (2015). Марке-тинговое изучение современного фармацевтического рынка ингаляци-онных бронхолитических ЛС для лечения хронической обструктивной болезни легких. Современные проблемы науки и образования, (1-1), 1850-1850.

16. Яковлева, Л. В., & Бондаренко, Д. В. (2015). Анализ доступности пре-паратов для лечения хронической обструктивной болезни легких укра-инских пациентов. Український біофармацевтичний журнал, (2), 4-10.

17. Payal, B., Kumar, A., & Saxena, H. (2021). Cost-minimization Analysis of Drugs Used in the Treatment of Asthma and COPD Diseases in India. Current Drug Therapy, 16(1), 83-88. https://doi.org/10.2174/1574885515999200813193250

18. Ray, A., Najmi, A., Khandelwal, G., & Sadasivam, B. (2020). A cost varia-tion analysis of drugs available in the indian market for the management of thromboembolic disorders. Cureus, 12(5). https://doi.org/10.7759/cureus.7964.

19. Bhandari, P. R. (2019). Analysis of Cost Variation of Hypolipidemics Drugs. Journal of Pharmaceutical and Biomedical Sciences, 9(4). https://doi.org/10.20936/jpbms/19/04/01.

20. Chaudhari, A., & Zaveri, J. R. (2019). Pharmacoecoeconomic study: A cost variation analysis of AKT drugs available in Indian market. Indian J Pharm Pharmacol, 6(1), 6-10. https://doi.org/10.18231/2393-9087.2019.0002.

21. Paunikar, A. P., & Bhave, K. A. (2015). Cost analysis of oral antidepressant drugs available in India. National Journal of Physiology, Pharmacy and Pharmacology, 5(5), 367-371. https://doi.org/10.5455/njppp.2015.5.1105201556.

22. Sarangi, S. C., Kaur, N., Tripathi, M., & Gupta, Y. K. (2018). Cost analysis study of neuropsychiatric drugs: Role of National List of Essential Medi-cines, India. Neurology India, 66(5), 1427. https://doi.org/10.4103/0028-3886.241345.

23. Кухтенко, А. С., Гладух, Е. В., & Назаркина, В. Н. (2017). Фармакоэко-номическая оценка лекарственных средств для лечения стенокардии и неврозов. Рецепт, 20(4), 516-523.

24. Nemchenko, A., Ie, G., Bondarenko, A., & Mishchenko, V. (2019). Phar-macoeconomic evaluation of availability of medicinal products used in symptomatic therapy of respiratory diseases. Norwegian Journal of Development of the International Science, (29-2).

25. Matera, M. G., Cazzola, M., & Page, C. (2021). Prospects for COPD treat-ment. Current Opinion in Pharmacology, 56, 74-84. https://doi.org/10.1016/j.coph.2020.11.003

26. Hasan, S. S., Capstick, T., Zaidi, S. T. R., Kow, C. S., & Merchant, H. A. (2020). Use of corticosteroids in asthma and COPD patients with or without COVID-19. Respiratory medicine, 170, 106045. https://doi.org/10.1016/j.rmed.2020.106045

27. Koarai, A., Sugiura, H., Yamada, M., Ichikawa, T., Fujino, N., Kawayama, T., & Ichinose, M. (2020). Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis. BMC pulmonary medi-cine, 20(1), 1-11. https://doi.org/10.1186/s12890-020-1152-8

28. Визель, А. А., Белевский, А. С., & Визель, И. Ю. (2020). Тиотропия бромид – к эффективности и доступности антихолинергической терапии в реальной клинической практике. Практическая пульмонология, (3).

29. Keeley, D., & Partridge, M. R. (2019). Emergency MDI and spacer packs for asthma and COPD. The Lancet Respiratory Medicine, 7(5), 380-382. https://doi.org/10.1016/S2213-2600(19)30046-3

30. Tashkin, D. P. (2016). A review of nebulized drug delivery in COPD. International Journal of Chronic Obstructive Pulmonary Dis-ease, 11, 2585. https://dx.doi.org/10.2147%2FCOPD.S114034